Загрузка...
Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients
BACKGROUND: The advent of targeted therapy for cancer treatment has brought about a paradigm shift in the clinical management of human malignancies. Agents such as erlotinib used for EGFR-mutant non-small cell lung cancer or imatinib for chronic myeloid leukemia, for instance, lead to rapid tumor re...
Сохранить в:
| Опубликовано в: : | PLoS One |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Public Library of Science
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4633116/ https://ncbi.nlm.nih.gov/pubmed/26536620 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0141665 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|